Search

Justin Leavitt (University of Utah) and colleagues report that the P22-encoded SieA protein is the only phage protein required for exclusion by the SieA system, blocking DNA injection by P22 and its relatives, but having no effect on infect

Status unconfirmed. Checked 2026-10-03. The primary purpose of this experimental therapy is to treat, with the aid of bacteriophages, patients with non-healing postoperative wounds or bone, upper respiratory tract, genital or urinary tract

Completed. Checked 2026-10-03. The PHAGE study is designed to determine if a commercial prebiotic product can change the composition of bacteria in the gut for improved intestinal health. A prebiotic is defined as an indigestible dietary co

Conflicting status. Checked 2026-10-03. This study will evaluate the safety of oral administration of EcoActive to patients with inactive Crohn's disease and how it affects the levels of AIEC in stool. A Phase 1/2a Double-Blind, Randomized,

Completed. Checked 2026-10-03. Study LBx-1001 is a multi-center randomized, double-blind study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of LBP-EC01 in patients with indwelling urinary catheters, or

Terminated. Checked 2026-10-03. This is a phase I/II trial designed to evaluate bacteriophage therapy in patients with urinary tract infections. A Phase I/II Study of Bacteriophage Therapy to Evaluate Safety, Tolerability, and Efficacy of T

Completed. Checked 2026-10-03. The BacterioPHAGE for Gastrointestinal Health-2 study is designed to determine if a commercial bacteriophage product can increase the survival and efficacy of probiotic bacteria that will be concurrently admin

Completed. Checked 2026-10-03. Phase 1b/2a, double-blind, randomized, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability and phage recovery profile of AP-PA02 multi-bacteriophage therapeutic ca

Unavailable. Checked 2026-10-03. Phage Treatment in Covid-19 Patients with Bacterial Co-Infections Expanded Access Study of Phage Treatment in Covid-19 Patients on Anti-Microbials for Pneumonia or Bacteremia/Septicemia Due to A. Baumannii,

Active, not recruiting. Checked 2026-10-03. The patients received bacteriophage therapy with a liquid piobacteriophage complex (liquid pyobacteriophage complex - PCL). PСL was administered via nebulizer inhalation to irrigate the tonsil muc

Completed. Checked 2026-10-03. This is a Phase 2 study with primary objective of looking whether YPT-01 phage therapy reduces sputum bacterial load in cystic fibrosis subjects with Pseudomonas aeruginosa. In addition, study evaluates the s

Withdrawn. Checked 2026-10-03. This is a study designed to evaluate bacteriophage therapy in patients with chronic prosthetic joint infections. Randomized Open Label, Parallel Group, Controlled Study to Evaluate the Safety and Surgery Spari

Status unconfirmed. Checked 2026-10-03. This study will evaluate a topical bacteriophage therapy product (BACTELIDE) as an adjunct to standard therapy for the prevention and treatment of pressure ulcers colonized with S. aureus, P. aerugino

Terminated. Checked 2026-10-03. This is a phase 2b randomized trial designed to evaluate bacteriophage therapy in subjects with diabetic foot osteomyelitis. Phase 2b Randomized, Parallel, Double-blind, Placebo-Controlled, Repeat Dose, Multi

Active, not recruiting. Checked 2026-10-03. The study is a first-in-human Phase 1/2a randomized, double-blind, placebo-controlled trial to assess the clinical safety and efficacy of ShigActive in healthy adults with experimental Shigella ch

Completed. Checked 2026-10-03. Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP SA02 as an Adjunct to Best Available Antibiotic T

Withdrawn. Checked 2026-10-03. This study will test the feasibility of a regimen of intraoperative (IO) and intravenous (IV) PhageBank™ bacteriophage therapy in conjunction with a DAIR procedure to cure chronic prosthetic joint infection (P

Withdrawn. Checked 2026-10-03. This is a study designed to evaluate bacteriophage therapy in patients with chronic prosthetic joint infections. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Eff

Recruiting. Checked 2026-10-03. This is a Phase 2 superiority study of LBP-EC01, a recombinant bacteriophage cocktail, with an initial open-label 3-arm pharmacokinetic (PK) lead-in portion of 30 patients to evaluate the optimal dosing regim

Completed. Checked 2026-10-03. A phase 2, multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety, phage kinetics, and efficacy of inhaled AP-PA02 administered in subjects with non-cystic fibrosis bronchiecta